Key Takeaways
- • THL Partners appointed Bruce Robertson, Ph.D., as Managing Director on its Healthcare investment team, according to a Business Wire announcement.
- • Robertson will focus on sourcing, evaluating, and executing investments in medtech products and life science tools and diagnostics, two of THL's healthcare Identified Sector Opportunities.
- • Robertson joins from H.I.G. Capital, where he was a Managing Director leading growth and control transactions across medical devices, digital health, and diagnostics.
- • THL reports over $8.7 billion deployed in healthcare across roughly 30 companies, with approximately $33 billion in aggregate enterprise value, and recently closed its tenth flagship fund with $6.35 billion in investable capital.
Summary
Boston-based THL Partners, a private equity firm focused on middle-market growth companies, has named Bruce Robertson, Ph.D., a Managing Director on its Healthcare investment team, according to a Business Wire announcement. Robertson will focus on sourcing, evaluating and executing investments across medtech products and life science tools and diagnostics, and will partner with management teams to support growth.
Robertson joins THL from H.I.G. Capital, where he served as a Managing Director and led a team investing in growth and control transactions across medical devices, digital health and diagnostics. His prior investments include Intact Vascular and Vesper Medical, both acquired by Philips; Apollo Endosurgery and Vertiflex, both acquired by Boston Scientific; and Neuwave Medical, acquired by Johnson & Johnson. Earlier roles include Managing Director at Toucan Capital, a healthcare products fund, and General Partner at GIV Venture Partners.
Joshua Nelson, Managing Director and Head of Healthcare at THL, said Robertson's ability to assess both the technology behind a product and the business opportunity around it would be a tremendous asset. The appointment strengthens THL's capabilities across two of its healthcare Identified Sector Opportunities (ISOs): MedTech Products and Life Science Tools and Diagnostics, which THL pairs with dedicated operating resources to accelerate growth.
THL states it has deployed over $8.7 billion in healthcare, including fund and co-investment capital, acquiring approximately 30 companies and supporting more than 170 add-on acquisitions, representing roughly $33 billion in aggregate enterprise value. The firm also recently closed its tenth flagship fund, including associated vehicles, with $6.35 billion in investable capital.
Robertson joins THL from H.I.G. Capital, where he served as a Managing Director and led a team investing in growth and control transactions across medical devices, digital health and diagnostics. His prior investments include Intact Vascular and Vesper Medical, both acquired by Philips; Apollo Endosurgery and Vertiflex, both acquired by Boston Scientific; and Neuwave Medical, acquired by Johnson & Johnson. Earlier roles include Managing Director at Toucan Capital, a healthcare products fund, and General Partner at GIV Venture Partners.
Joshua Nelson, Managing Director and Head of Healthcare at THL, said Robertson's ability to assess both the technology behind a product and the business opportunity around it would be a tremendous asset. The appointment strengthens THL's capabilities across two of its healthcare Identified Sector Opportunities (ISOs): MedTech Products and Life Science Tools and Diagnostics, which THL pairs with dedicated operating resources to accelerate growth.
THL states it has deployed over $8.7 billion in healthcare, including fund and co-investment capital, acquiring approximately 30 companies and supporting more than 170 add-on acquisitions, representing roughly $33 billion in aggregate enterprise value. The firm also recently closed its tenth flagship fund, including associated vehicles, with $6.35 billion in investable capital.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.